[go: up one dir, main page]

WO2002007670A3 - Intracellular delivery system for protein phosphatases - Google Patents

Intracellular delivery system for protein phosphatases Download PDF

Info

Publication number
WO2002007670A3
WO2002007670A3 PCT/IL2001/000688 IL0100688W WO0207670A3 WO 2002007670 A3 WO2002007670 A3 WO 2002007670A3 IL 0100688 W IL0100688 W IL 0100688W WO 0207670 A3 WO0207670 A3 WO 0207670A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
protein phosphatases
intracellular delivery
protein
phosphatases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2001/000688
Other languages
French (fr)
Other versions
WO2002007670A2 (en
Inventor
Sara Lavi
Ronit Satchi-Fainaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Priority to US10/343,094 priority Critical patent/US20040101941A1/en
Priority to AU2001282427A priority patent/AU2001282427A1/en
Publication of WO2002007670A2 publication Critical patent/WO2002007670A2/en
Anticipated expiration legal-status Critical
Publication of WO2002007670A3 publication Critical patent/WO2002007670A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The subject invention relates to a polymer-based intracellular delivery system for protein phosphatases. This delivery system can be used to deliver protein phosphatases for any disease or disorder in which it is desirable to elevate protein phosphatase activity, particularly for tumor therapy. Novel protein phosphatases are also disclosed.
PCT/IL2001/000688 2000-07-26 2001-07-26 Intracellular delivery system for protein phosphatases Ceased WO2002007670A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/343,094 US20040101941A1 (en) 2001-07-26 2001-07-26 Intracellular delivery system for protein phosphatases
AU2001282427A AU2001282427A1 (en) 2000-07-26 2001-07-26 Intracellular delivery system for protein phosphatases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22097500P 2000-07-26 2000-07-26
US60/220,975 2000-07-26
US66871400A 2000-09-22 2000-09-22
US09/668,714 2000-09-22

Publications (2)

Publication Number Publication Date
WO2002007670A2 WO2002007670A2 (en) 2002-01-31
WO2002007670A3 true WO2002007670A3 (en) 2003-10-02

Family

ID=26915376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000688 Ceased WO2002007670A2 (en) 2000-07-26 2001-07-26 Intracellular delivery system for protein phosphatases

Country Status (2)

Country Link
AU (1) AU2001282427A1 (en)
WO (1) WO2002007670A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007671A2 (en) * 2000-07-26 2002-01-31 Ramot-University Authority For Applied Research And Industrial Development Ltd. Intracellular delivery system for protein phosphatases and other polypeptides
US6372205B1 (en) * 1997-06-11 2002-04-16 The School Of Pharmacy, University Of London Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372205B1 (en) * 1997-06-11 2002-04-16 The School Of Pharmacy, University Of London Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
WO2002007671A2 (en) * 2000-07-26 2002-01-31 Ramot-University Authority For Applied Research And Industrial Development Ltd. Intracellular delivery system for protein phosphatases and other polypeptides

Also Published As

Publication number Publication date
AU2001282427A1 (en) 2002-02-05
WO2002007670A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
USD463655S1 (en) Insulated winter boot
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2004024757A3 (en) Modified pna molecules
AP2005003232A0 (en) Combination therapy for hyperproliferative diseases.
WO2007071055A8 (en) Compositions and methods for modulating gated ion channels
WO2000003753A3 (en) Microdisperse drug delivery systems
AU2001258095A1 (en) Drug delivery systems for photodynamic therapy
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
MXPA03007903A (en) Highly flexible transdermal therapeutic system having nicotine as active substance.
WO2003030927A3 (en) Use of thymulin-like peptides for making pain-relieving medicines
WO2001077080A3 (en) Pyrazole compounds having anti proliferative activity
HUP0101788A3 (en) Harvester, especially self-propelled chopper
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
WO2007149594A3 (en) Modified ribonucleases
EP0979309A4 (en) OLIGONUCLEOTIDES WITH BETTER BIOAVAILABILITY
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
WO1999047655A3 (en) Human nucleic acid fragments with heightened expression in normal breast tissue
WO2002007670A3 (en) Intracellular delivery system for protein phosphatases
EP1133997A3 (en) Treatment of immune diseases with beta-interferon
WO2007137149A3 (en) Use of cathepsin k antagonists in bone production
WO2001014415A3 (en) Egfh2 genes and gene products

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2002134469

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10343094

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP